Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases

Tsutomu Takeuchi, Kouichi Amano, Hideto Kameda, Toru Abe

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

It is now evident that biological agents targeting on the tumor necrosis factor (TNF) have not only induce a substantial clinical response, but also inhibit the structural damage in patients with Rheumatoid Arthritis (RA). Upon the great success of anti-TNF biologicals as the therapeutic modalities of choice in the treatment of inflammatory disorders of unknown etiology, the details of TNF, and anti-TNF biological agents are extensively reviewed, particularly, focusing on those used against RA. So far, nearly one million patients are expected to expose to these agents worldwide. In Japan, chimeric monoclonal antibody to TNFα, infliximab has been approved for Crohn's disease in 2002, RA in 2003, and TNF receptor 2-IgG Fc fusion protein, etanercept had just approved for RA in 2005. Full human anti-TNFa monoclonal antibody, adalimumab is now under clinical trials. Safety profiles of these agents, based on the exposure to one hundred million patients for up to ten years, are summarized. While the experiences using biological agents in Japan are rather limited, the unique circumstances in Asian countries should been taken into account. In this respect, the issues around the anti-TNF biologicals in Japan are finally discussed.

Original languageEnglish
Pages (from-to)191-202
Number of pages12
JournalAllergology International
Volume54
Issue number2
DOIs
Publication statusPublished - 2005 Jun
Externally publishedYes

Fingerprint

Biological Factors
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Japan
Monoclonal Antibodies
Receptors, Tumor Necrosis Factor, Type II
Crohn Disease
Immunoglobulin G
Clinical Trials
Safety
Therapeutics
Proteins

Keywords

  • Monoclonal antibody
  • RA
  • Receptor antagonist
  • TNF

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases. / Takeuchi, Tsutomu; Amano, Kouichi; Kameda, Hideto; Abe, Toru.

In: Allergology International, Vol. 54, No. 2, 06.2005, p. 191-202.

Research output: Contribution to journalArticle

Takeuchi, Tsutomu ; Amano, Kouichi ; Kameda, Hideto ; Abe, Toru. / Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases. In: Allergology International. 2005 ; Vol. 54, No. 2. pp. 191-202.
@article{b0a1979dd97947b790c66d33e26f42b8,
title = "Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases",
abstract = "It is now evident that biological agents targeting on the tumor necrosis factor (TNF) have not only induce a substantial clinical response, but also inhibit the structural damage in patients with Rheumatoid Arthritis (RA). Upon the great success of anti-TNF biologicals as the therapeutic modalities of choice in the treatment of inflammatory disorders of unknown etiology, the details of TNF, and anti-TNF biological agents are extensively reviewed, particularly, focusing on those used against RA. So far, nearly one million patients are expected to expose to these agents worldwide. In Japan, chimeric monoclonal antibody to TNFα, infliximab has been approved for Crohn's disease in 2002, RA in 2003, and TNF receptor 2-IgG Fc fusion protein, etanercept had just approved for RA in 2005. Full human anti-TNFa monoclonal antibody, adalimumab is now under clinical trials. Safety profiles of these agents, based on the exposure to one hundred million patients for up to ten years, are summarized. While the experiences using biological agents in Japan are rather limited, the unique circumstances in Asian countries should been taken into account. In this respect, the issues around the anti-TNF biologicals in Japan are finally discussed.",
keywords = "Monoclonal antibody, RA, Receptor antagonist, TNF",
author = "Tsutomu Takeuchi and Kouichi Amano and Hideto Kameda and Toru Abe",
year = "2005",
month = "6",
doi = "10.2332/allergolint.54.191",
language = "English",
volume = "54",
pages = "191--202",
journal = "Allergology International",
issn = "1323-8930",
publisher = "Japanese Society of Allergology",
number = "2",

}

TY - JOUR

T1 - Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases

AU - Takeuchi, Tsutomu

AU - Amano, Kouichi

AU - Kameda, Hideto

AU - Abe, Toru

PY - 2005/6

Y1 - 2005/6

N2 - It is now evident that biological agents targeting on the tumor necrosis factor (TNF) have not only induce a substantial clinical response, but also inhibit the structural damage in patients with Rheumatoid Arthritis (RA). Upon the great success of anti-TNF biologicals as the therapeutic modalities of choice in the treatment of inflammatory disorders of unknown etiology, the details of TNF, and anti-TNF biological agents are extensively reviewed, particularly, focusing on those used against RA. So far, nearly one million patients are expected to expose to these agents worldwide. In Japan, chimeric monoclonal antibody to TNFα, infliximab has been approved for Crohn's disease in 2002, RA in 2003, and TNF receptor 2-IgG Fc fusion protein, etanercept had just approved for RA in 2005. Full human anti-TNFa monoclonal antibody, adalimumab is now under clinical trials. Safety profiles of these agents, based on the exposure to one hundred million patients for up to ten years, are summarized. While the experiences using biological agents in Japan are rather limited, the unique circumstances in Asian countries should been taken into account. In this respect, the issues around the anti-TNF biologicals in Japan are finally discussed.

AB - It is now evident that biological agents targeting on the tumor necrosis factor (TNF) have not only induce a substantial clinical response, but also inhibit the structural damage in patients with Rheumatoid Arthritis (RA). Upon the great success of anti-TNF biologicals as the therapeutic modalities of choice in the treatment of inflammatory disorders of unknown etiology, the details of TNF, and anti-TNF biological agents are extensively reviewed, particularly, focusing on those used against RA. So far, nearly one million patients are expected to expose to these agents worldwide. In Japan, chimeric monoclonal antibody to TNFα, infliximab has been approved for Crohn's disease in 2002, RA in 2003, and TNF receptor 2-IgG Fc fusion protein, etanercept had just approved for RA in 2005. Full human anti-TNFa monoclonal antibody, adalimumab is now under clinical trials. Safety profiles of these agents, based on the exposure to one hundred million patients for up to ten years, are summarized. While the experiences using biological agents in Japan are rather limited, the unique circumstances in Asian countries should been taken into account. In this respect, the issues around the anti-TNF biologicals in Japan are finally discussed.

KW - Monoclonal antibody

KW - RA

KW - Receptor antagonist

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=21144458091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144458091&partnerID=8YFLogxK

U2 - 10.2332/allergolint.54.191

DO - 10.2332/allergolint.54.191

M3 - Article

VL - 54

SP - 191

EP - 202

JO - Allergology International

JF - Allergology International

SN - 1323-8930

IS - 2

ER -